Desacetyl--MSH predominates over -MSH during development but whether it is biologically active and has a physiological role is unclear. We compared the effects of 0.3µg/g/day desacetyl--MSH with that of 0.3µg/g/day -MSH on postnatal body growth by administering the peptides subcutaneously daily for postnatal days 0-14 and also used a 2DE-gel based proteomic approach to analyse protein changes in hypothalami, the relay centre for body weight and growth regulation, after 14 days of treatment. We found the growth rate between days 1-10 was significantly decreased by desacetyl--MSH but not by -MSH, but by day 14, a time reported for development of a mature pattern of hypothalamic innervation, both peptides had significantly increased neonatal growth compared to PBS treated control rats. Desacetyl--MSH significantly increased spleen weight but -MSH had no effect. Alpha-MSH significantly decreased kidney weight but desacetyl--MSH had no effect. Both desacetyl--MSH and -MSH significantly decreased brain weight. By 14 days both peptides significantly changed expression of a number of hypothalamic proteins, specifically metabolic enzymes, cytoskeleton, signalling and stress response proteins. We show that peripherally administered desacetyl--MSH is biologically active and induces responses that can differ from those for -MSH. In conclusion, desacetyl--MSH appears to be an important regulator of neonatal rat growth.
INTRODUCTION
The pivotal role of the melanocortin system in regulation of appetite, metabolism, body size, and body weight is demonstrated clearly by the human melanocortin 4 receptor (MC4R) (24, 65) and pro-opiomelanocortin (POMC) (34) variants, three knockout mouse models (POMC, MC3R and MC4R)(10, 14, 29, 70), the spontaneously occurring dominant agouti mouse (68) and a mouse ectopically over-expressing agouti gene related peptide (AGRP) (26), all of which promote obesity. Still unresolved though, are the roles of each POMC-derived peptide and the central melanocortin signaling pathways.
The melanocortin peptides, -melanocyte stimulating hormone (MSH) and desacetyl--MSH, are two endogenous peptides derived from a precursor protein,
POMC, through post-translational processing (46). N-terminal acetylation of desacetyl--MSH to form -MSH occurs in secretory vesicles just prior to exocytosis (42, 66), but not all desacetyl--MSH is acetylated since desacetyl--MSH is present
in the circulation and brain of rodents and humans. The major form of plasma immunoreactive MSH is -MSH in rodents and desacetyl--MSH in humans (22, 40) and the relative abundance of these two MSH peptides is developmentally regulated
MATERIALS AND METHODS

Reagents and Materials
Alpha-MSH and desacetyl--MSH were purchased from Bachem California (CA, USA). Prior to use, -MSH and desacetyl--MSH were converted to their hydrochloride salts (16), lyophilised, and stored as aliquots at -80°C. The integrity of the peptides after this procedure was confirmed by (i) matrix-assisted laser desorption-ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) (Voyager DE-Pro, Applied Biosystems, Foster City, CA, USA) and (ii) assessment of peptide biological activity following exposure to HEK293 cells stably expressing MC4R and measurement of adenylyl cyclase activity, as previously described (45).
All gels and apparatus used in 2-DE were purchased from Amersham Pharmacia Biotech (Uppsala, Sweden). All chemicals were purchased from BDH (Biolab, Auckland, NZ), bovine serum albumin Fraction V (BSA) was purchased from Sigma (Biolab, Auckland, NZ) and sequencing grade trypsin was purchased from Promega (Madison, WI, USA). All animal procedures undertaken were approved by the Animal Ethics Committee at the University of Auckland.
Subcutaneous injections into neonatal rats
To compare peripheral effects of -MSH and desacetyl--MSH on neonatal rat growth, nine pups from each litter were injected subcutaneously with equal doses (0.3 µg/g body weight/day) of -MSH (3 litters), desacetyl--MSH (3 litters), or vehicle control (4 litters) for 14 days. These same doses had previously been used to determine significant effects for these peptides on neonatal rat body growth (39).
Adult female Wistar rats were housed in plastic cages and kept on a 12 h dark/light cycle. Animals received rat pellets (NRM New Zealand) and tap water ad libitum and were mated with males of the same strain. Each litter of newborn Wistar rats was SDS-PAGE gels in the second dimension. Silver-stained gels were digitised with consistent image size and settings using a Transparent Media Adapter on a ScanMaker E6 scanner (Microtek, Hsinchu, Taiwan). The images were imported into Melanie II software (Bio-Rad, Hercules, CA, USA) and the protein spots on each gel were detected and quantitated. All gels were aligned and matched to a reference gel (the gel containing the most protein spots) so that features from each gel that were paired with a spot in the reference gel would form a group. The volume of each protein spot (area x optical density) was measured and normalised as percentage of total volume of all spots detected in a given gel (% Vol [% volume of spots = the sum of intensity values of every pixel in the area outlined for the spot as a percentage of the total staining intensity volume of the gel]), which was then exported to STATISTICA for statistical analysis.
Identification of proteins of interest
Sample Preparation
For preparative gels, protein samples (100 µl) were loaded via the in-gel rehydration method (Amersham Pharmacia Biotech) and separated as described above for our analytical 2DE-gels, stained with Colloidal Coomassie Blue stain (CCB; 1.3 M ammonium sulfate, 34% v/v methanol, 3% v/v phosphoric acid, 1.2 mM Coomassie Blue R-250) for 24 h at 21°C and then destained with 5% v/v acetic acid until a clear background was achieved. Proteins of interest were excised and then digested in-gel with trypsin using a modified method previously reported by Rosenfeld et al (56). We used a lower salt concentration (25mM NH 4 HCO 3 ) and less trypsin (0.2-0.3µg) than specified in the original method.
LC/MS/MS analysis
Peptide from trypsin digested proteins were extracted with water and then twice with 50% acetonitrile/5% formic acid in an ultrasonic bath for 15 min and then analysed using a LCQ Deca ion trap mass spectrometer fitted with a nanospray ESI interface (Thermo Finnigan, San Jose, California, U.S.A.) coupled to a Surveyor ), the preliminary raw score (Sp) was above 300, and the dCn (delta correlation) score was above 0.1 (36). The quality of each match was confirmed by analysis of the MS/MS spectra with the Fuzzy Ion de novo sequencing function of the SEQUEST Browser software. Selected DTA files were further analysed by Lutefisk, a programme for the de novo interpretation of MS/MS spectra (63). Proteins with at least two peptide matches and more than 10% sequence coverage were considered significant.
Statistics
The growth curves for the three treatment groups based on body weight data collected over 14 days of treatment were analysed by a General Linear Model (SAS system) using a nested within nested design with repeated measures to separate sources of variation between litters and between individual rats. The independent factors were Treatment effects, Litter (Treatment) effects, and Rat (Litter*Treatment) effects. Nine pups from each litter were assigned to a treatment group, thus forming a double nested design. The 'individual rat' variable was nested with the 'litter' variable, which in turn was nested with the 'treatment group' variable. The postnatal body weights measured sequentially on different days were treated as repeated measures. Organ weight data were analysed first by determining the correlation between organ weights and final body weights for each group. Data for organs that significantly correlated with body weight were normalised for body weight (g/100g body weight). Body weight and normalised organ weight data from day 14 were analysed by one-way ANOVA with Bonferroni post-hoc test (Systat10 package, SPSS Inc., Chicago IL, USA). Body and organ weights are presented as mean ± SE.
The significance of treatment effects on protein spots in 2DE-gels was assessed by analysing the normalised data (%Vol) of individual protein spots of each group using the non-parametric Mann-Whitney U test (60). A p-value < 0.05 was considered statistically significant for all statistical methods used.
RESULTS
Differential effects of -MSH and desacetyl--MSH on body weight change in neonatal rats
Desacetyl--MSH significantly reduced the day 1-14 postnatal growth curve for newborn rats (p<0.05) during daily subcutaneous peptide injection compared to a PBS control group ( Figure 1A ). This contrasted with no significant effect on postnatal growth curve seen with -MSH compared with the PBS treated control group. However, on postnatal day 14, when body weights were measured approximately 1.5 h after injection, both -MSH and desacetyl--MSH treated pups were significantly heavier (p<0.05) than the PBS treated control animals ( Figure 1B ).
Differential effects of -MSH and desacetyl--MSH on organ weights
The correlation between organ weight and body weight on day 14 in control (PBS) and treatment ( -MSH and desacetyl--MSH) groups was significant (p<0.05) for brain, spleen, heart, kidney and liver, but not for lung. Comparison of normalised organ weights (g/100g body weight) between treatment and PBS control groups showed that organ weight was significantly decreased (p<0.05) for brain by both -MSH and desacetyl--MSH, for kidney by -MSH only, and significantly increased for spleen by desacetyl--MSH only (Table 1) .
Peripheral injection of -MSH and desacetyl--MSH induced different patterns of protein changes in the hypothalamus
Alpha-MSH significantly changed protein expression levels for 32 out of 1209 matched protein groups compared to PBS control rats ( Figure 2A ) and desacetyl--MSH significantly changed 33 out of 1212 matched protein groups compared to PBS control rats ( Figure 2B ). Some of these protein spots were increased and others were decreased (indicated in Figure 2A and B). Only 9 proteins (p1079, p1327, p1445, p1458, p1505, p1520, p1610, p1790, and p1854) with significantly altered expression compared to PBS control were common to both -MSH and desacetyl--MSH treated groups (Figure 2A and B).
Identification of proteins of interest
We identified proteins of interest using LC/MS/MS analysis employing collision-induced dissociation to yield peptide fragmentation spectra that were used to query the NCBI nr database using the SEQUEST algorithm. This analysis identified 24 of the 65 protein spots that were significantly changed by peptide treatments (Supplement Table) , with more than 2 peptides matching to each identified protein.
Using extent of protein coverage as an indication of confidence of protein identification, 12 of the identified proteins had more than 10% protein coverage, and 4/12 of these were increased by both peptide treatments (Tables 2 and 3 ). The proteins were grouped according to their main cellular function, such as cytoskeletal, metabolic, signalling and stress response proteins, and the significant effect of each peptide treatment indicated (Table 3) .
Two proteins, p1610 and p1588, were identified as stathmin. The observation that these two proteins appeared as different spots of similar molecular mass but different pI on the 2DE-gels suggested that p1588 could be a phosphorylated isoform of stathmin. A phosphate group would add negative charge to the protein, resulting in a shift towards the acidic side of the gel. To test this, the MS/MS data files from both p1610 and p1588 from which tryptic peptide sequences were ascertained were analysed using a differential modification to serine (Ser), threonine (Thr) or tyrosine Page 13 of 47 (Tyr) residues of +79.98 corresponding to the mass of a phosphate group. Indeed, a data file from p1588 matched the sequence ESVPEFPLS*PPK with a phosphate group added to the second Ser, corresponding to the Ser at position 38 of the amino acid sequence of rat stathmin. Reanalysis clearly showed that the modified peptide can on its own explain the gel shift observed. No other phosphorylated peptides were seen for stathmin.
DISCUSSION
We show here that 0.3µg/g/day desacetyl--MSH, peripherally administered daily for the first 2 weeks of life to neonatal rats is biologically active and induces responses that differ from those for -MSH similarly administered. When the growth curves for the three treatment groups were compared desacetyl--MSH significantly slowed neonatal rat growth whereas -MSH had no effect. Desacetyl--MSH significantly increased spleen weight but -MSH had no effect. Alpha-MSH, on the other hand, significantly decreased kidney weight and desacetyl--MSH had no effect. Both desacetyl--MSH and -MSH significantly decreased brain weight and increased body weight at postnatal day 14.
Results from this study demonstrate for the first time that desacetyl--MSH and -MSH show different effects on rat neonatal growth. Circulating levels of desacetyl--MSH have been reported to be more abundant than -MSH at birth, but in rodents this is reversed after birth with N-acetyl transferase activity in rat pituitary peaking at approximately two months of age, then declining (11). It is possible that the relative abundance of -MSH and desacetyl--MSH peptides influences neonatal growth with increased peripheral desacetyl--MSH slowing growth in the neonate. In contrast to our findings that desacetyl--MSH and -MSH both increased rat body weight at postnatal day 14 but not prior to this, Mauri et al (39) reported significant trophic effects from rat postnatal day 2-14 with peripheral administration of the same dose of desacetyl--MSH while the same dose of -MSH had no significant effect.
Trophic effects of -MSH were only seen with a 10-fold higher dose from postnatal day 4-14. Some of their observed peptide effects on various organ weights also differed from our observations here. These differences between our results and those of Mauri et al might be due to different rodent genetic backgrounds (their rat strain was not stated), for example, and in the relative abundance of these two peptides.
Another possibility is the statistical model used for data analysis (see Statistics section); their experimental design and statistical analysis were not stated.
In adult mice peripherally administered desacetyl--MSH has previously been found to significantly increase body weight, muscle and adipose tissue weight, and food intake (62). It is not surprising that these results differ from our data in the neonatal rat since the hypothalamus, which is critical for regulation of appetite, body weight and metabolism in the adult, is not fully developed until after postnatal day 14 in rodents (53) . The physiological roles of leptin are also different in neonate compared to adult rats. In adults, leptin is an adipocyte-derived hormone that signals the hypothalamus about energy stores and regulates key metabolic pathways involved in energy homeostasis. However, in newborn rats, leptin is critical for the development of neuron projections in the hypothalamus (Table 3) . Both peptides increased levels of ATP synthase, stathmin, cofilin, tubulin beta and a protein similar to protein kinase C inhibitor. Gel spots corresponding to truncated proteins were present at reduced molecular mass and often altered pI values from those expected or observed for the intact protein. These truncations retained some of the peptide complement of the parent protein and may not be artifacts of the sample preparation; they may be natural degraded forms of enzymes reflecting accelerated turnover. Alpha-MSH increased a fragment of ATP synthase (p1351) while desacetyl--MSH increased a fragment of ATP synthase (p1339). ATP synthase couples ATP generation to respiratory chain oxidation, and 'uncoupling' of this process leads to proton leakage, resulting in energy dissipated as heat (1, 32, 55) . Interestingly, ATP synthase itself has been shown to be a target protein for an anorectic peptide, enterostatin (6) . In this study, -MSH also increased protein expression of adenylate kinase 1 (AK1) (p1360), a member of the adenylate kinase family of phosphotransfer enzymes essential in the maintenance of cellular energetics in tissues with highly variable energy demand, such as muscle and brain (30, 31). Genetic ablation of AK1 disturbs muscle energetic economy and decreases tolerance to metabolic stress (30). These hypothalamic protein changes suggest that MSH peptides are associated with mitochondrial metabolism and energy utilization.
We show here that peripherally administered -MSH and desacetyl--MSH also change hypothalamic expression levels of several cytoskeletal proteins such as cofilin, tubulin, and stathmin. Both peptides increased levels of a fragment of tubulin -polypeptide, cofilin, and stathmin. Cofilin, also known as the actin depolymerization factor ADF, has been shown to bind directly to actin filaments and promote their disassembly (38, 49). Stathmin, also known as oncoprotein 18, is an ubiquitous cytoplasmic protein that interacts with tubulin dimers and increases the catastrophe rate (the transition from growing to shrinking) of microtubules (3, 4) .
Both BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor) have been reported to phosphorylate stathmin in PC12 cells, mostly on Ser25, which corresponds to the major site phosphorylated by mitogen-activated protein kinase vitro (12, 20) and blocking the expression of stathmin using antisense oligonucleotides prevented NGF-induced differentiation of PC12 cells into sympathetic-like neurons (19). Stathmin is expressed at higher levels in neonatal rat brain compared to adult brain (25) and is involved in neurogenesis in adult mouse brain (33). In our study, desacetyl--MSH increased levels of a phosphorylated isoform of stathmin (p1588) and the MS/MS data indicates that this is phosphorylated at Ser38. Interestingly, phosphorylation of stathmin at Ser38 is thought to be via cyclin-dependent kinases during mitosis, and results in reduced microtubuledestabilising activity of stathmin (5, 35, 37) . There are at least 14 isoforms of stathmin that migrate on 2DE-gels: two unphosphorylated, and 12 increasingly phosphorylated proteins (48, 71) and it has been suggested that regulation of microtubule dynamics by stathmin phosphorylation could be involved in fundamental processes associated with the reorganisation of the cytoskeleton such as neuronal differentiation or synaptic plasticity. The observation that desacetyl--MSH increased the Ser38 phosphorylated isoform of stathmin suggests desacetyl--MSH may reduce the microtubule destabilising effect and oppose the action of -MSH, which increases stathmin expression but not phosphorylation.
Reorganization of the cytoskeleton through modification of microtubule dynamics is important in neuronal differentiation and synaptic plasticity, and some of the changes in hypothalamic protein expression we observed might be associated with direct or indirect roles for both MSH peptides in synaptic plasticity. Leptin plays a critical neurotrophic role in the hypothalamus during the neonatal period studied here (8, 52) and leptin also regulates desacetyl--MSH and -MSH levels (27). It is possible therefore that leptin's neurotrophic effects are in part mediated though the MSH peptides. Alpha-MSH improves short term memory in rats (18) and the behavioural effects of -MSH are permanent in rats treated peripherally postnatally but only transitory in animals treated as adults (2) . Hence, the hypothalamic protein changes observed from chronic treatment of -MSH and desacetyl--MSH imply a modified neuronal network that might lead to behavioural changes in adult rats.
Our proteomic analysis has produced a snapshot of the peptide changes induced by -MSH and desacetyl--MSH peptide treatments. We have identified several hypothalamic proteins using 2DE-gel based proteomic techniques, that have not previously been associated with melanocortin peptide signaling. Moreover, we show that peripherally administered desacetyl--MSH but not -MSH, to new born rats slows their growth over 10 days and then their body weights catch up and overtake control rats. Alpha-MSH on the other hand stimulates body weights between postnatal days 10 and 14. After 14 days of peripheral peptide treatment both peptides induced changes in hypothalamic protein expression and while many of the changes were similar for the two peptides, there were also some differences. We have clearly shown that peripherally administered desacetyl--MSH, like -MSH, is biologically active in vivo and that it differs from -MSH in some of its responses. Finally, we demonstrate the application of 2DE-gel based proteomics as a discovery system to identify hypothalamic proteins that are directly, or indirectly, responsive to either - Spot numbers correspond to protein spot numbers in Figure 2 . LC/MS/MS spectra of spots were searched against NCBI rat database using SEQUEST software from Bioworks 3.1, Thermo Finnigan. Table shows NCBI GenPep accession number, theoretical protein molecular weight (MW) predicted from the matched sequence, ion charge, raw cross correlation score (Xcorr) and % total protein identified (refer to Methods).
MSH or desacetyl--MSH stimulation in vivo.
GRANTS
Proteins with more than 10% protein coverage were included in the Table. 
